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response
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Background: Numerous studies have investigated the effects of isolated CLA supplementation on glucose homeostasis
in humans and rodents. However, both the amount and relative abundance of CLA isomers in supplemental form are
not representative of what is consumed from natural sources. No study to date has examined the effects of altered CLA
isomer content within a natural food source. Our goal was to increase the content of the insulin desensitizing CLAt10,c12
isomer relative to the CLAc9,t11 isomer in cow’s milk by inducing subacute rumenal acidosis (SARA), and subsequently
investigate the effects of this milk fat on parameters related to glucose and insulin tolerance in rats.
Methods: We fed female rats (~2.5 to 3 months of age) CLA t10,c12 –enriched (SARA) butter or non-SARA butter based
diets for 4 weeks in either low (10% of kcal from fat; 0.18% total CLA by weight) or high (60% of kcal from fat; 0.55% total
CLA by weight) amounts. In an effort to extend these findings, we then fed rats high (60% kcal) amounts of SARA or
non-SARA butter for a longer duration (8 weeks) and assessed changes in whole body glucose, insulin and pyruvate
tolerance in comparison to low fat and 60% lard conditions.
Results: There was a main effect for increased fasting blood glucose and insulin in SARA vs. non-SARA butter groups
after 4 weeks of feeding (p < 0.05). However, blood glucose and insulin concentration, and maximal insulin-stimulated
glucose uptake in skeletal muscle were similar in all groups. Following 8 weeks of feeding, insulin tolerance was impaired
by the SARA butter, but not glucose or pyruvate tolerance. The non-SARA butter did not impair tolerance to glucose,
insulin or pyruvate.
Conclusions: This study suggests that increasing the consumption of a naturally enriched CLAt10,c12 source, at least in
rats, has minimal impact on whole body glucose tolerance or muscle specific insulin response.
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The most abundant conjugated linoleic acid (CLA) isomers
are CLAc9,t11 and CLAt10,c12 which make up approximately
76% and 1% of total naturally occurring CLA, respectively
[1,2]. CLA supplements (equal mix of CLAt10,c12 and
CLAc9,t11 isomers) have become popular due to their* Correspondence: ddyck@uoguelph.ca
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unless otherwise stated.purported ability to cause desirable changed in body mass
and composition in humans [3-6]. However, it is in mice
that the most dramatic loss of body fat i.e. lipoatrophy is
observed in response to CLA [7-9]. Interestingly, insulin
resistance has also been observed as an outcome of mixed
CLA supplementation in both mice [7,8] and humans [3-6]
and appears linked to the CLAt10,c12 isomer. Human con-
sumption of CLA from food sources is approximately
200 mg per day, which is much lower than amounts takenral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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than that used in the majority of rodent studies when ad-
justed to body mass [10]. Whether altered CLA content
in natural food sources, particularly that of the poten-
tially detrimental CLAt10,c12 isomer, poses a risk in
terms of developing glucose intolerance or insulin re-
sistance is completely unknown.
No study to date has examined the effects of altered
CLA isomer content derived from a natural food source,
such as milk fat. CLA cannot be produced endogenously,
and so the only source of CLA for humans is dietary
consumption of the meat, milk and derived products
of ruminant animals [11]. Dairy products are a major
contributor to the dietary intake of CLA. In order to
increase milk production, Canadian dairy cows are
often fed a high grain, low forage ration, that may pro-
duce a condition known as subacute rumenal acidosis
(SARA), which is defined as a decrease in rumenal pH
below 5.6 for extended periods (4–6 hrs) during a 24-
hr period [12,13]. This decrease in pH results in a sig-
nificant increase in the production of the CLAt10,c12
isomer due to incomplete biohydrogenation of polyun-
saturated fatty acids [14]. In light of the evidence that
high CLAt10,c12 intake can potentially cause insulin re-
sistance, we endeavored to determine whether there is
a health risk related to changes in glucose tolerance
and insulin response as a result of increased CLAt10,c12
content in dairy products.
Thus, our goal was to nutritionally manipulate the ra-
tio of the two main CLA isomers in milk fat from dairy
cows by inducing SARA, and subsequently investigate
the effects of an increased content of CLA t10,c12 in this
milk fat on parameters related to glucose and insulin
tolerance in rats. To this end, rodent diets were pro-
duced containing low (10% kcal) or high (60% kcal)
amounts of fat derived from SARA and non-SARA but-
ter. Female Sprague–Dawley rats were fed CLA t10,c12 –
enriched (SARA) butter, and non-SARA (control) butter
based diets for 4 to 8 weeks. The effects of the SARA and
non-SARA butter based diets on fasting blood glucose
and insulin concentrations, whole body glucose and insu-
lin tolerance, as well as insulin stimulated glucose uptake
in isolated skeletal muscle were evaluated in two separate
experiments after 4 to 8 weeks of feeding. We hypothe-
sized that rats fed the high CLA t10,c12 (SARA) butter,
but not the control (non-SARA) butter based diets,
would demonstrate elevated fasting blood glucose and
insulin, impaired insulin stimulated glucose uptake in
skeletal muscle, as well as impaired whole body glucose
and insulin tolerance. If this hypothesis is correct, subse-
quent studies may be warranted to determine whether
consumption of dairy products that are enriched in
CLA t10,c12 increases the risk of impaired glucose and
insulin tolerance in humans.Methods
Ethics statement
All procedures were carried out in accordance with the
recommendations of the Canadian Council of Animal
Care, and were approved by the Animal Care Committee
at the University of Guelph (Animal Utilization Proto-
cols 09R046 and 1515). All surgeries on rodents were
performed under sodium pentobarbital anesthesia and
all efforts made to prevent discomfort and suffering.
Dairy cows and rations
Six lactating Holstein cows housed at the Ponsonby
Dairy Research Centre, University of Guelph, Guelph,
Ontario were used in this study. The cows were ran-
domly assigned to one of two dietary treatments for a
total of 21 days: a high-forage diet (n = 4 cows) or a
SARA-inducing high-grain diet (n = 2 cows). The high-
forage diet was designed to promote a stable rumen en-
vironment and maintain an optimal rumenal pH. This
was achieved by feeding a total mixed ration with high
effective fiber and low grain levels (10% of DM (dry mat-
ter) high moisture corn). In contrast to this, the SARA
diet provided a lower but adequate amount of fiber, and
also included a combination of soybean oil (2% of DM)
and readily fermentable carbohydrates in the form of
wheat and barley pellets (20% of DM). The oil and grain
pellets were mixed and fed as a top-dressing. This diet
was intended to create a condition in which cows would
experience SARA-related alterations in rumen microbial
fermentation and a subsequent shift in the biohydro-
genation pathway, leading to elevated levels of CLA t10,c12
in milk fat. Cows were fed twice daily, and received the
SARA-inducing top dressing in the morning feed between
800–900 h. All animals were handled and cared for in
accordance with the Canadian Council on Animal Care
regulations, and as approved the Animal Care Committee
at the University of Guelph.
Milk collection and processing
Milking of all cows took place twice daily at 0500 and
1600 h. Milk collection for the experiment took place on
days 13 through 21 and was performed on 7 separate days
throughout this period. Each cow was milked with separ-
ate bucket milkers to avoid cross-contamination between
treatments. The milk from each animal was then poured
into stainless steel canisters, immediately placed on ice,
and transferred to the University of Guelph Food Science
Department where it was pooled by treatment and proc-
essed to make unsalted butter. The fatty acid profile of the
butter was analyzed as previously reported [15].
Study design
This study was conducted to address two objectives. The
first objective was to determine whether feeding rats
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SARA) and SARA butter for a relatively short period of
time (4 weeks) was sufficient to alter basic indices of in-
sulin sensitivity (fasting blood glucose and insulin), as
well as insulin response and glucose uptake in skeletal
muscle, which is by mass the largest tissue responsible
for the clearance and management of blood glucose.
Our initial findings indicated little effect of the SARA-
based butter on our measured parameters. We therefore
conducted further experiments to address our second
(follow-up) objective, which was whether a more pro-
longed exposure to a high-SARA butter diet would lead
to impaired glucose tolerance and insulin resistance. To
this end, we fed rats diets high in control (non-SARA)
and SARA butter (60% kcal), for an extended period
(8 weeks) on whole body indices of glucose tolerance
and insulin sensitivity, including glucose, insulin and
pyruvate tolerance tests. The effects of these butter-
based diets were compared to low fat (10% kcal) control
and high (60% kcal) lard based diets, which have predict-
able effects on glucose and insulin tolerance. In our ex-
perience, 4–8 weeks feeding of a high fat (lard) based
diet is sufficient to induce skeletal muscle insulin resist-
ance [16,17] in lean female rats. Due to limited quan-
tities of our custom manufactured butter, we were able
to utilize 14–15 rats per dietary group to examine our
initial objective, but only 5 rats per group to examine
our second objective.
We chose to use lean rats, rather than mice, for this
study as mice demonstrate a rather unique lipody-
strophic response to CLA supplementation [7-9] which
does not occur in humans. The majority of studies
examining the effects of CLA on insulin sensitivity and
glucose tolerance in rats have utilized the fa/fa Zucker
rat. While we recognize the value of the Zucker rat as a
model for obesity and diabetes, we felt that as an initial
study examining the effects of naturally modified CLA
content on glucose tolerance and insulin sensitivity, a
more “modest” model would be more suitable. Our sub-
sequent studies will examine the outcome of feeding
butter with altered CLA profiles on fa/fa Zucker rats.
Objective 1 - Shorter term effects of SARA vs. non-SARA
butter on fasting glucose and insulin, and muscle insulin
response
Rodents and diets
Female Sprague–Dawley rats (approximately 120 g; Charles
River Laboratories, Quebec, Canada) were group-housed in
a controlled environment with a reverse 12:12-h light–dark
cycle during a 5 day acclimation period. During this time
rats had ad libitum access to Purina standard rodent chow
and fresh water. Rats were then placed in individual
cages and randomly assigned to one of 4 dietary treat-
ments (n = 14-15 per group): low fat control (non-SARA) butter diet (10% kcal from control butter), high
fat control butter (60% kcal from non-SARA butter),
low fat SARA butter diet (10% kcal from SARA butter),
or high fat SARA butter diet (60% kcal from SARA but-
ter). Rats remained on these diets for 4 weeks. The di-
ets were made by mixing the control and SARA butter
with a powdered diet premix (D12492px) formulated by
Research Diets Inc. (New Brunswick, NJ, USA). Fresh
batches of each diet were mixed every few days through-
out the trial. Rodents were fed fresh food each day in the
morning and weighed twice weekly. In this first study, ani-
mals were pair-fed across all four dietary treatments in
order to minimize potential differences in weight gain.
Following 4 weeks of feeding, rats were fasted overnight
before experimental procedures were performed. All pro-
cedures were approved by the Animal Care Committee at
the University of Guelph.
Tissue and blood sampling
Muscle isolation Rats were anesthetized with an intra-
peritoneal injection of pentobarbital sodium (5 mg/100 g
body mass) and the hindlimb soleus (SOL) muscle was
carefully divided into longitudinal strips using a 27-gauge
needle. The SOL strips were then incubated to measure
glucose transport under basal and maximal insulin stimu-
lated conditions as we have previously done [16,17].
Glucose transport Upon excision, SOL strips were im-
mediately placed in pre-gassed vials (95% O2, 5% CO2)
in a gentle shaking bath (30°C) and equilibrated for
30 minutes in KHB (0.1% fatty acid free BSA) containing
8 mM glucose and 32 mM mannitol, in the absence or
presence of insulin (10 mU/mL). Strips were then washed
twice (10 min each) with glucose-free KHB (4 mM pyru-
vate, 36 mM mannitol). After washing, SOL strips were
incubated for 20 min (insulin-stimulated, 10 mU/mL) or
40 min (basal) in KHB (4 mM pyruvate, 8 mM 3-O-[3H]
methyl-D-glucose (800 μCi/mmol), 28 mM [14C]mannitol
(60 μCi/mmol)]. Muscles were blotted, trimmed of ten-
dons, weighed, and finally digested at 95°C for 10 min in
1 mL NaOH (1 M). 200 μL aliquots of muscle digest were
placed in 7 mL plastic scintillation vials in duplicate, 5 mL
of CytoScint scintillation cocktail was added to each vial,
and samples were left to quench overnight. Intracellular
3-O-[3H] methyl-D-glucose was quantified and used to
calculate glucose transport as described previously (23).
Insulin signaling proteins Sol strips were first equili-
brated in a similar manner to the first step of the glucose
transport assay (above), but without insulin. Strips were
then incubated for 10 min in the presence or absence of
insulin (10 mU/mL) for the determination of phosphory-
lated (activated) Akt. Once incubation was complete, the








g kcal g kcal g kcal
Casein 200 800 200 800 200 800
L-Cysteine 3 12 3 12 3 12
Cornstarch 315 1260 0 0 0 0
Maltodextrin 35 140 125 500 125 500
Sucrose 350 1400 68.8 275.2 68.8 275.2
Cellulose 50 0 50 0 50 0
Soybean Oil 25 225 25 225 25 225
Lard 20 180 0 0 245 2205
Butter 0 0 295 2165 0 0
Mineral Mix 10 0 10 0 10 0
Dicalcium phosphate 13 0 13 0 13 0
Calcium phosphate 5.5 0 5.5 0 5.5 0
Potassium citrate 16.5 0 16.5 0 16.5 0
Vitamin mix 10 40 10 40 10 40
Choline bitartate 2 0 2 0 2 0
Dye 0.05 0 0 0 0.05 0
Total 1055 4057 824 4017 774 4057
kcal/g 3.85 4.88 5.24
%kcal from fat 10 60 60
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until future Western blot analyses.
Blood Terminal blood collection after an overnight fast
was performed following skeletal muscle extraction via car-
diac puncture. A glucometer reading (OneTouch Ultra 2,
LifeScan Inc., Milpitas, CA, USA) of whole blood glucose
was made at this time. Blood samples were collected in
heparinized tubes and centrifuged at 9 300 g for 5 minutes
at 4°C. Plasma was stored at −80°C for analysis of glucose
(via glucometer) and insulin (rat insulin RIA kit; Millipore,
St. Charles, MO, USA).
Western blot analyses
Sol muscle (~40 mg) was homogenized (1:9 w/v dilution)
in ice-cold buffer suitable for protein extraction and pre-
serving phosphorylation states of proteins, containing
50 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 50 mM
NaF, 5 mM sodium pyrophosphate, 10% (vol/vol) glycerol,
1% (vol/vol) Triton X-100, 2 mg/ml leupeptin, 2 mg/ml
aprotinin, 2 mg/ml pepstatin, 1 mM dithiothreitol, and
1 mM phenylmethylsulfonyl fluoride. Homogenates were
sonicated for 5 seconds and centrifuged at 20,000 g for
20 min at 4°C. The supernatant was removed, and protein
content was determined using BSA as standards. Fifty mi-
crograms of this whole tissue lysate protein were solubi-
lized in 4X Laemmeli’s buffer and boiled at 95°C for
5 min, resolved by SDS-PAGE, and wet transferred to
polyvinylidene difluoride (PVDF) membranes (1 h, 100 V).
The membranes were blocked for 1 h in 7.5% BSA and
then incubated for 1 h with a primary antibody for Ser473
(Santa Cruz Biotechnology, Santa Cruz, CA) phosphory-
lated Akt. Membranes were washed and then incubated
for 1 h with the secondary antibody (anti-rabbit). Mem-
branes were washed again, and proteins were detected
using enhanced chemiluminescence method. Equal load-
ing was confirmed using nonspecific protein staining with
Ponceau-S stain (Sigma Aldrich, Oakville, ON, Canada).
Objective 2 - Longer term effects of SARA vs. non-SARA
butter on whole body glucose, insulin and pyruvate
tolerance tests
Rodents and diets
Twenty female Sprague Dawley rats (mean body weight
138 g ± 1.5 g) were obtained from Charles River (Quebec,
Canada) and individually housed in a 12-hour reversed
light/dark cycle with free access to water and a standard
chow diet for a 1 week acclimation period. Rats were
randomly assigned to one of 4 dietary treatment groups
(n = 5 per group): i) low fat diet (LFD; 10% kcal from fat),
ii) control (non-SARA) butter (60% kcal from fat), iii)
SARA butter (60% kcal from fat), or iv) LARD (60% kcal
from fat). Composition of the low fat, butter-based, and
lard diets is shown in Table 1. The 60% LARD group wasincluded as a positive control condition i.e. one in which
we expected to see the development of glucose and/or in-
sulin intolerance. In order to provide a more realistic op-
portunity for the various butter diets to cause any
potential negative effects on glucose and insulin tolerance,
rats received food ad libitum for an 8 week duration. Body
mass and food intake were monitored weekly for the en-
tire experimental period. All protocols were approved by
the Animal Care Committee, and were in compliance with
the guidelines outlined by the Canadian Council on Ani-
mal Care at the University of Guelph.
A negative control low fat diet (LFD) containing
10% kcal from fat (5.5% soybean oil and 4.5% lard;
D12450B) and a positive control high fat diet (LARD)
containing 60% kcal from fat (5.5% soybean oil and
54.5% lard; D12492) were obtained from Research Diets,
New Jersey, USA. A premix excluding lard, but otherwise
identical in composition to the LARD diet (D12492px),
was used to blend custom butter-based diets with 60% kcal
from fat (5.5% soybean oil and 54.5% butter). Due to the
higher moisture content of butter, the amount of butter
added to make up 60% kcal from fat was based on the
analysis of custom butters (fat content 83.2% ± 0.45). But-
ter diets were prepared by blending 295 g of butter with
528.8 g of diet premix in a commercial grade food mixer
(Hobart Canada, Ontario, Canada). Fresh batches of each
Table 2 Content of saturated, monounsaturated, and
polyunsaturated fatty acids in non-SARA (control) and
SARA diets (g/100 g)
Non-SARA Diet SARA Diet
g/100 g
butter fat
g/100 g diet* g/100 g
butter fat
g/100 g diet*
SFA 71 ± 0.5 21 ± 0.2 53 ± 1.3a 15 ± 0.4a
PUFA 3 ± 0.1 1 ± 0.01 6 ± 0.4a 2 ± 0.1a
MUFA 26 ± 0.1 7 ± 0.2 41 ± 0.9a 12 ± 0.3a
Total 100 29 100.0 29
n3 FA 0.6 ± 0.01 0.2 ± 0.003 0.7 ± 0.03 0.2 + 0.01
n6 FA 2.0 ± 0.05 0.6 ± 0.01 2.8 ± 0.2a 0.8 + 0.06a
Data presented as mean plus/minus standard error, in g/100 g of butter fat or
prepared diet (*60% kcal from butter). asignificantly different from non-SARA
butter (p < 0.05). n = 4 batches of non-SARA butter, and 4 batches of SARA
butter. SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA,
monounsaturated fatty acids.
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stored at 4C.
Tolerance tests
During the 8th (final) week, whole body glucose, insulin
and pyruvate tolerance tests were performed. Tests were
separated by 1–2 days.
Glucose tolerance test (GTT) Rats were fasted for
6 hours and a basal blood glucose concentration was de-
termined with blood from the tail tip using a glucometer
(OneTouch Ultra 2, LifeScan Inc., Milpitas, CA, USA). A
glucose bolus (2 g glucose/kg body weight) was adminis-
tered by intraperitoneal injection and blood glucose con-
centrations were evaluated at 15, 30, 45, 60, 90 and
120 minutes post injection.
Insulin tolerance test (ITT) Basal blood glucose was
determined in fed rats with blood from the tail tip as de-
scribed above. Blood glucose levels were determined at
10, 20, 30, 45, 60, 90 and 120 minutes after an intraperi-
toneal insulin injection (0.75 U insulin/kg body weight).
Pyruvate tolerance test (PTT) Rats were fasted for
6 hours and basal blood glucose was determined as de-
scribed above. A pyruvate bolus (2 g pyruvate/kg body
weight, adjusted to pH 7.35) was administered by intra-
peritoneal injection and blood glucose levels were eval-
uated at 15, 30, 45, 60, 90 and 120 minutes post
injection.
Statistical analyses
Statistical analyses used in this study compared means
with a two-way ANOVA in the experiments examining
the first objective (butter type X level of fat), and a one-
way ANOVA in the experiments examining the second
objective. For whole body tolerance tests, group means
were compared using the area under the curve (AUC)
taken from baseline blood glucose (mmol/L) for each
animal; the ITT used the AUC below baseline blood glu-
cose. A Fisher’s post-hoc test was used to compare treat-
ment groups. All statistical analyses were calculated
using Prism 5.0 software (GraphPad Software Inc. 2008,
San Diego, USA). Statistical significance was accepted at
p ≤ 0.05.
Results
Altered FA profile of milk fat (butter)
The SFA, PUFA and MUFA composition of non-SARA
and SARA butters is shown in Table 2. The t10,c12 CLA
isomer was increased by ~ 10-fold (p < 0.001) in the
SARA butter (0.10 g/100 g FA) compared to control but-
ter (0.01 g/100 g FA; Table 3). In fact, all measured CLA
isomers demonstrated some increase in the SARA butterrelative to the control butter, including the c9 t11 isomer
(>2-fold), which is the most naturally abundant CLA
isomer.Shorter term effects of SARA vs. non-SARA butter on fast-
ing glucose and insulin, and muscle insulin response
Rodent feed intake and body mass
There was no significant difference in body mass (start, ~
175 g, terminal, ~270 g) or caloric intake throughout the
study (week 1, ~70 kcal/day; week 4, ~85 kcal/day) amongst
the groups.Blood and plasma measurements
Blood and plasma measurements are shown in Table 4.
There was a significant main effect for treatment (SARA vs.
non-SARA) on blood glucose and plasma insulin (p < 0.05).
That is, blood glucose and plasma insulin were greater in
the SARA vs. non-SARA conditions, regardless of the
amount of fat/butter in the diet. However, there was no sig-
nificant difference in fasting blood glucose between the 4
dietary groups following the 4 week trial. Fasting plasma in-
sulin was significantly greater in the low SARA butter fed
animals compared to all other groups (p < 0.05).Glucose transport in ex vivo muscles
Basal glucose transport in isolated SOL muscle did not dif-
fer amongst dietary groups (Figure 1). Insulin-stimulated
glucose transport was significantly increased above basal
rates (p < 0.05), but was not different across treatments.
Phosphorylation (activation) of the serine residue on
Akt, a key upstream protein of the insulin signalling
pathway, was also increased significantly with insulin
treatment (p < 0.05), but there were no differences amongst
dietary treatments (Table 5; Figure 2).
Table 3 Content of linoleic acid (18:2 9c, 12c) and conjugated linoleic acid isomers in non-SARA (control) and SARA
diets (g/100 g)
Fatty acid Non-SARA diet SARA diet
g/100 g of butter fat g/100 g diet* g/100 g of butter fat g/100 g diet*
18:2 9c, 12c 1.72 ± 0.03 0.51 ± 0.01 2.50 ± 0.225a 0.75 ± 0.06a
18:2 11 t, 15c 0.07 ± 0.005 0.02 ± 0.0002 0.39 ± 0.002a 0.11 ± 0.001a
18:2 9c, 11 t 0.49 ± 0.15 0.15 ± 0.005 1.16 ± 0.144a 0.34 ± 0.04a
18:2 9 t, 11c 0.01 ± 0.00 0.0003 ± 0.000 0.08 ± 0.004a 0.03 ± 0.001a
18:2 10 t, 12c 0.01 ± 0.001 0.0003 ± 0.000 0.10 ± 0.003a 0.03 ± 0.001a
18:2 9 t, 11 t and 10 t, 12 t 0.03 ± 0.004 0.01 ± 0.001 0.08 ± 0.004a 0.03 ± 0.001a
18:2 11 t, 13 t 0.01 ± 0.002 0.0003 ± 0.001 0.03 ± 0.004a 0.01 ± 0.001a
Total CLA 0.62 ± 0.05 0.18 ± 0.007 1.84 ± 0.16a 0.55 ± 0.04a
Data presented as mean plus/minus standard deviation, in g/100 g of butter fat or prepared diet (*60% kcal from butter). The main CLA isomers, 9c, 11 t and 10 t,
12c are bolded. asignificantly different from non-SARA butter (p < 0.05). n = 4 batches of non-SARA butter, and 4 batches of SARA butter.
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whole body glucose, insulin and pyruvate tolerance tests
Rodent feed intake and body mass
During the 8 weeks of high-fat feeding, the growth
curves were similar between groups and there was no
statistical difference between the group means of final
body weight (~340 g). The average energy intake over
the 8 week period, when normalized to body weight, was
nearly identical in all groups (~0.3 kilocalories/g BW/
















Similar to that reported with the shorter intervention,
there were no significant differences in fasting blood glu-
cose concentrations between groups following 8 weeks
of their respective diets (LFD, 5.22 ± 0.19 mM; control
butter, 5.30 ± 0.11 mM; SARA butter, 5.54 ± 0.16 mM;










20Tolerance tests and glucose area under the curve (AUC)
Total area under the curve (AUC) for the glucose toler-
ance tests did not show any significant differences be-
tween dietary groups (Figure 3). Response to the insulinTable 4 Blood glucose and plasma insulin concentrations
after 4 weeks feeding of butter based diets
Dietary group Blood glucose (mM) Plasma insulin (pM)
Low control butter diet 9.1 ± 0.2 (13) 6.1 ± 0.3 (13)
Hhigh control butter diet 9.1 ± 0.3 (15) 5.4 ± 0.4 (15)
Low SARA butter diet 9.7 ± 0.3 (15) 7.7 ± 0.4 (15)b
High SARA butter diet 9.4 ± 0.4 (14) 5.2 ± 0.5 (14)
Pooled control butter diet 9.1 ± 0.2 (28) 5.8 ± 0.2 (28)
Pooled SARA butter diet 9.6 ± 0.2 (29)a 6.5 ± 0.4 (29)a
Data are presented as mean plus/minus standard error. Sample size is shown
in parentheses. asignificantly different from pooled control butter diet
(p < 0.05); bsignificantly different from all other groups (p < 0.05).and pyruvate tolerance tests, however, did differ between
groups. Total glucose AUC during the insulin tolerance
tests was significantly reduced in both the LARD and
SARA groups compared to the LFD group (p < 0.05), indi-
cating a lower rate of glucose clearance i.e. reduced insulin
sensitivity. The AUC of the glucose response during the
pyruvate tolerance test was significantly greater in the
LARD group compared to LFD (p < 0.05), but the butter





















Figure 1 Insulin stimulated glucose uptake in isolated soleus
muscle. Data are presented as mean plus standard error. Dashed
line represents average basal (unstimulated) glucose uptake in all
groups. *significantly different from basal (unstimulated) glucose
uptake (p < 0.05). SOL strips were equilibrated for 30 minutes in gassed
KHB (0.1% fatty acid free BSA) at 30C containing 8 mM glucose and
32 mM mannitol, in the absence or presence of insulin (10 mU/mL).
Strips were washed twice (10 min each) with glucose-free KHB (4 mM
pyruvate, 36 mM mannitol). After washing, SOL strips were incubated
for 20 min (insulin-stimulated, 10 mU/mL) or 40 min (basal) in KHB
(4 mM pyruvate, 8 mM 3-O-[3H] methyl-D-glucose (800 μCi/mmol),
28 mM [14C]mannitol (60 μCi/mmol)].
Table 5 Akt serine phosphorylation in incubated soleus





Low control butter diet 100 ± 10 (13) 220 ± 19c (13)
High control butter diet 100 ± 16 (15) 260 ± 29c (15)
Low SARA butter diet 97 ± 14 (15) 254 ± 31c (15)
High SARA butter diet 120 ± 19 (14) 252 ± 26c (14)
Data are expressed in arbitary densiometry units relative to the low control
butter diet (set to 100). Data are presented as mean plus/minus standard
error. Sample size is shown in parentheses. csignificantly different from basal
condition (p < 0.05).
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This study was conducted to evaluate the potential nega-
tive health effects relating to insulin sensitivity of natur-
ally occurring dietary CLAt10,c12 , given the studies
showing that supplemental doses of this isomer have a
negative impact on insulin resistance in humans [3-6,18].
To our knowledge, this is the first study to examine the
metabolic consequences of consuming naturally altered
CLAt10,c12 content in a food source. To that end, we pro-
duced a 60% high fat diet with the fat component com-
posed almost entirely of butter produced from milk
collected from dairy cows suffering from SARA, a condi-
tion that can sometimes result from the practice in the
dairy industry of feeding a high grain, low forage diet to
milk-producing cows [12-14]. This butter represents, in
reality, what is probably the most naturally enriched
source of CLA t10,c12 available for human consumption. In
this study, we examined the impact of shorter (4 weeks)
and longer (8 weeks) term consumption of a diet highly
enriched in CLA t10,c12 in lean healthy rats. Specifically,
we examined the effects of i) 4 weeks consumption of low
(10% of total kcal) and high amounts (60% of total kcal) of
control (non-SARA) and SARA butter based diets on
plasma glucose and insulin, as well as insulin signaling
and glucose uptake in isolated rodent skeletal muscle, and
ii) 8 weeks consumption of high amounts of control and
SARA butter (60% of total kcal) on whole body glucose,
insulin and pyruvate tolerance. The second intervention
was longer in duration (8 vs. 4 weeks) in order to increase
the opportunity to observe any potential detrimental effect
of the CLA t10,c12 -enriched diet if such an effect existed.Figure 2 Representative blot for Akt serine phosphorylation in incuba
Order of Lanes: low control butter (basal), low control butter (insulin), high
(basal), low SARA butter (insulin), high SARA butter (basal), high SARA butteResults from the present study indicate that within a
relatively short period of time (4 weeks), there was a sig-
nificant main effect for treatment (SARA vs. non-SARA)
on blood glucose and plasma insulin (p < 0.05). That is,
blood glucose and plasma insulin were greater in the
SARA vs. non-SARA conditions, regardless of the amount
of fat/butter in the diet. However, this effect was small in
magnitude. Furthermore, based on the individual groups,
there were no significant differences in fasting glucose or
insulin concentrations. This was also confirmed in the
second, longer term (8 week) intervention following
which no significant change in fasting blood glucose
was detected. Furthermore, the ex vivo stimulation of
muscle glucose uptake and phosphorylation of Akt in
response to a maximal insulin concentration was not
affected by consuming butter for 4 weeks with a greater
content of CLAt10,c12. Finally, tolerance tests (glucose,
insulin and pyruvate) were performed after consuming
8 weeks of the low fat, and various high fat diets. Cal-
culated AUC demonstrated significant impairment, or
worsening, of insulin and pyruvate tolerance tests in
the LARD fed animals, as would be predicted. SARA
butter fed animals also demonstrated an impaired insulin
tolerance test relative to the low fat fed group, but glucose
and pyruvate tolerance were not adversely affected.
Collectively, our results suggest that in contrast to the
findings of studies feeding higher amount of purified
CLAt10,c12, the consumption of a diet containing natur-
ally elevated amounts of CLAt10,c12 poses relatively little
risk in terms of impaired muscle insulin response and
whole body glucose tolerance. This may be due to sev-
eral reasons including the relatively lower consumption
of CLA in the current study (0.18 to 0.55 g CLA/100 g
diet) compared to previous rodent studies using supple-
mental CLA (1.5 g/100 g diet). Furthermore, the relative
abundance of all CLA isomers increased in the SARA
butter such that the ratio between CLAc9,t11 and CLAt10,c12
was approximately 11:1, which is considerably greater than
the 1:1 ratio of supplemented CLA. In addition, the dur-
ation of CLA consumption may also be a factor. Other
studies have reported effects of CLAt10,c12 in mice, at simi-
lar concentrations to ours (0.5%) over a longer time course
(6 months), including increases in muscle mass [19] and
decreases in whole body insulin response [20]. In theted soleus muscle under basal and insulin stimulated conditions.






























































































































Figure 3 Calculated area under the curve for glucose, insulin
and pyruvate tolerance tests. Data are presented as mean plus
standard error. *significantly different from control (low fat butter) group
(p < 0.05). Glucose tolerance test. Rats were fasted for 6 hours. A glucose
bolus (2 g glucose/kg body weight) was administered by intraperitoneal
injection and blood glucose concentrations were evaluated at 15, 30,
45, 60, 90 and 120 minutes post injection. Insulin tolerance test. Rats
were fasted for 3 hours. Blood glucose levels were determined at 10, 20,
30, 45, 60, 90 and 120 minutes after an intraperitoneal insulin injection
(0.75 U insulin/kg body weight). Pyruvate tolerance test. Rats were fasted
for 6 hours. A pyruvate bolus (2 g pyruvate/kg body weight, adjusted to
pH 7.35) was administered by intraperitoneal injection and blood
glucose levels were evaluated at 15, 30, 45, 60, 90 and 120 minutes
post injection.
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of our custom manufactured butter, which necessitated
a somewhat shorter time course of feeding. Therefore,
we cannot be certain as to whether a longer period of
feeding CLA might not have demonstrated a clearer
negative outcome.
High dairy intake has been associated with a reduced
risk for type 2 diabetes [21,22] without increasing the
risk of cardiovascular disease [23]. A recent study dem-
onstrated that high consumption of low fat dairy low-
ered fasting insulin by 9% and insulin resistance by 11%
in obese individuals [24]. An obvious limitation of our
current study is that the sole source of dietary fat was
butter. Few studies focus on butter as the sole source of
dietary fat. One study demonstrated that healthy men
consuming a high fat, butter-based diet supplemented
with 5.5 g/day of mixed isomer CLA showed elevated
markers of lipid peroxidation compared to butter alone,
but no significant differences in fasting insulin, glucose
or insulin resistance; however, there was no non-butter
control used in this study [25]. In rats, the addition of
milk to a diet high in sucrose was able to improve insu-
lin sensitivity [26]. Dairy fat is complex in composition
and contains numerous bioactive components that may
potentially impact insulin sensitivity. For example, butter
contains the short chain fatty acid butyric acid, which
when supplemented in the diets of obese, high fat-fed
mice improves fasting glucose, insulin and insulin toler-
ance [27]. In the current study, we specifically attempted
to increase the content of the CLA t10,c12 isomer relative
to that of the CLAc9,t11 isomer. However, it is possible
that changes in other components of butter may have
influenced the outcome. Indeed, the lack of any clear
negative metabolic consequence to increased CLAt10,c12
may be due in part to compensatory effects due to
altered amounts of other components, including other
CLA isomers which were all observed to increase in the
SARA butter. While this may make interpretation more
difficult in terms of cause and effect, it does point to the
need to study the effects of altered CLA content in the
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isomer supplements.
Finally, it should be acknowledged that the choice of
model will likely have significant bearing on the out-
come. The majority of rodent studies examining the im-
pact of CLA supplementation have utilized lean mice
and obese fa/fa Zucker rats. In the current study, we did
not use mice as they demonstrate a rather unique lipoa-
trophic response to CLA supplementation [7-9]. It is
also mice which consistently show impairments in insu-
lin sensitivity with CLA supplementation [7,8,20]. Al-
though we plan to examine the impact of feeding our
altered butters on fa/fa Zucker rats, we decided to first
examine the effect of naturally altered CLA on lean rats,
as they are a less “extreme” model. Less information is
available regarding the effects of CLA supplementation
on lean rats. However, in the Zucker rat, a commonly
used rodent model of obesity and insulin resistance,
CLA supplementation is generally observed to improve
insulin sensitivity and inflammation [28,29]. Therefore, it
is possible the general lack of negative consquences to
feeding high amount of SARA butter in the current
study is due to the choice of lean rats as a model i.e. that
mice are more susceptible to the effects of CLAt10,c12
than are lean rats. Nonetheless, rats have been used by
many laboratories including our own to study the effects
of high fat diets on insulin sensitivity and in our opinion,
represent a valid choice of species.
Conclusion
In conclusion, the outcome of this study does not indi-
cate an increased risk of glucose intolerance, or skeletal
muscle insulin resistance in healthy rodents consuming
a natural dietary fat with a higher than normal CLAt10,c12
content. This finding, combined with the fact that much
smaller amounts of butter would be consumed in humans,
as well as the relatively modest effects on insulin resistance
of pharmaceutical doses in human clinical trials [3-6,18],
suggests that the elevated CLAt10,c12 content of dairy
products are unlikely to pose a risk to healthy individuals.
Nonetheless, the potentially adverse effects of CLAt10,c12
may be more pronounced in those already overweight or
obese, compared to lean individuals [5,18,30,31]. There-
fore it may be prudent to evaluate the effects of high
CLAt10,c12 butter in a model of established obesity, or in
high risk groups such as those with existing insulin resist-
ance or type 2 diabetes.
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